Losamix

Brand Name:

Losamix-H

Generic Name:

Losartan Potassium & Hydrochlorothiazide Tablet

Dosage Form:

Film coated, Oral, Tablet (Losartan/Hydrochlorothizide): 50/12.5 mg

Brand Name:

Losamix-H

Generic Name:

Losartan Potassium & Hydrochlorothiazide Tablet

Dosage Form:

Film coated, Oral, Tablet (Losartan/Hydrochlorothizide): 50/12.5 mg

Indication & usage:

Anti-hypertension:  Combine an angiotensin II receptor (type AT1) antagonist and a diuretic, hydrochlorothiazide.Losamix-H is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients.Hypertensive Patients with Left Ventricular Hypertrophy: Losamix-H is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. 

Dosage & Administration:

Hypertension Dosing must be individualized. The usual starting dose of losartan is 50 mg once daily, with 25 mg recommended for patients with intravascular volume depletion (e.g., patients treated with diuretics) and patients with a history of hepatic impairment. Losartan can be administered once or twice daily at total daily doses of 25 to 100 mg. If the antihypertensive effect measured at trough using once-a-day dosing is inadequate, a twice-a-day regimen at the same total daily dose or an increase in dose may give a more satisfactory response.

Hydrochlorothiazide is effective in doses of 12.5 to 50 mg once daily and can be given at doses of 12.5 to 25 mg as Losamix-H. To minimize dose-independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy. 

Adverse Reaction:

The following adverse events were also reported at a rate of 1% or greater, but were as, or more, common in the placebo group in studies of essential hypertension: asthenia/fatigue, diarrhea, nausea, headache, bronchitis, pharyngitis.

Contraindication:

  • Losamix-H is contraindicated in patients who are hypersensitive to any component of this product.

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.

  • Do not co-administer Aliskiren with Losamix-H in patients with diabetes.

Drug interaction:

  • Losartan, did not affect the pharmacokinetics or pharmacodynamics of a single dose of warfarin.
  • Losartan did not affect the pharmacokinetics of oral or intravenous digoxin.
  • There is no pharmacokinetic interaction between losartan and hydrochlorothiazide.
  • Co-administration of losartan and cimetidine led to an increase of about 18% in AUC of losartan but did not affect the pharmacokinetics of its active metabolite.
  • Co-administration of losartan and phenobarbital led to a reduction of about 20% in the AUC of losartan and that of its active metabolite.
  • A somewhat greater interaction (approximately 40% reduction in the AUC of active metabolite and approximately 30% reduction in the AUC of losartan) has been reported with rifampin.
  • Fluconazole, an inhibitor of cytochrome P450 2C9, decreased the AUC of the active metabolite by approximately 40%, but increased the AUC of losartan by approximately 70% following multiple doses.
  • Lithium generally should not be given with thiazides

Warning & Precautions:

  • Drugs that act directly on the renin-angiotensin system can cause fetal and neonatal morbidity and death when administered to pregnant women. Several dozen cases have been reported in the world literature in patients who were taking angiotensin converting enzyme inhibitors. When pregnancy is detected, Losamix-H should be discontinued as soon as possible.
  • The use of drugs that act directly on the renin-angiotensin system during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death.
  • Infants with histories of in utero exposure to an angiotensin II receptor antagonist should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as means of reversing hypotension and/or substituting for disordered renal function.
  • Losamix-H is not recommended for patients with hepatic impairment who require titration with losartan. The lower starting dose of losartan recommended for use in patients with hepatic impairment cannot be given using Losamix-H.
  • Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.
  • Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.
  • Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus.
  • General Hypersensitivity:
  • Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.
  • All patients receiving thiazide therapy should be observed for clinical signs of fluid or electrolyte imbalance: hyponatremia, hypochloremic alkalosis, and hypokalemia. Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Warning signs or symptoms of fluid and electrolyte imbalance, irrespective of cause, include dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, confusion, seizures, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.
  • Hypokalemia may develop, especially with brisk diuresis, when severe cirrhosis is present, or after prolonged therapy. 

Pregnancy & Lactation:

Pregnancy Categories C (first trimester) and D (second and third trimesters).

Lactation: It is not known whether losartan is excreted in human milk, but significant levels of losartan and its active metabolite were shown to be present in rat milk. Thiazides appear in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. 

Storage & condition:

Store below 25°C. Protect from light and moisture.

Packaging:

Carton containing 3blister strips of 10 tablet each.

License Holder

Koushan Pharmed

MAH

Koushan Pharmed

 

    • 1stFloor,No.15,Padidar Alley,Africa Blvd.
    • Tel: +98 2188197145
    • Fax:+98 2188197153
    • Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow us on:

We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. Cookie policy. I accept cookies from this site. Agree